evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 40%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).

1 finding from 1 review